Skip to content

Safety of Cardiac Pacemakers in 1.5T Tesla MRI

Studie Zur Sicherheit Von Medtronic Schrittmachern Bei Magnetresonanz-Bildgebungsverfahren an 1,5 Tesla-Systemen Study to Evaluate Safety Medtronic Pacemakers in MR Imaging at 1.5T Tesla)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00336011
Enrollment
75
Registered
2006-06-12
Start date
2002-12-31
Completion date
2006-01-31
Last updated
2006-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Diseases

Keywords

pacemaker, magnetic resonance imaging, safety

Brief summary

To evaluate short-term and long-term effects by MR imaging on the technical and functional status of Medtronic pacemakers.

Detailed description

The presence of a cardiac pacemaker (PM) is currently considered an absolute contraindication to MR imaging, and most patients with PM are excluded from having MRI. In 2002 there were approximately 2.4 million patients in the US with cardiac PM, and this number is growing by 80,000 annually. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement 1, demonstrating the need for a practical and safe approach for performing MRI on PM patients. The aim of this study is to develop a strategy for safe performance of MR imaging at 1.5T, which included exclusion of pacemaker dependent patients and those requiring imaging of the thorax, restriction of specific absorption rate (SAR) values to minimize the risk of lead heating, and PM reprogramming to avoid interference from time varying gradient fields. The safety of this approach is then evaluated in a large group of PM patients including assessment of potential myocardial thermal injury by measuring serum troponin I and pacing capture thresholds, and performing a 3-month follow-up to evaluate long-term effects.

Interventions

DEVICEMagnetic resonance imaging

Sponsors

Medtronic
CollaboratorINDUSTRY
University Hospital, Bonn
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Urgent need for an MRI examination * Presence of a Medtronic PM system manufactured between 1993 and 2004 * Stable pacemaker physical parameters * Battery voltage \> 2.7 V * Battery impedance \< 2000 Ohm * Battery estimated remaining lifetime \> 6 months * Lead impedances 200-2000 Ohm * Stable pacing parameters * Pacing capture threshold \<2.5V at a pulse duration of 0.4ms * Sensing \> 5mV * Minimum 3 months since pacemaker and lead implantation

Exclusion criteria

* PM system manufacturer other than Medtronic * History of ventricular tachycardia (VT) or ventricular fibrillation * Unstable angina * Myocardial infarction within the previous 3 months * Cardiothoracic surgery within the previous 3 months * Complete atrioventricular block * Absolute pacemaker dependence * Heart rate \< 40 bpm or * Heart rate \< 60 bpm producing neurological symptoms * Presence of an abdominal pacemaker with lead length \> 70 cm * Presence of MRI incompatible bioimplants or other MRI incompatible materials * Request for an MR examination of the chest, including the heart, breasts and thoracic spine

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026